迈瑞医疗投资者交流日：始终以积极态度应对外部挑战

Core Viewpoint - Mindray Medical's performance growth has slowed down since the second half of 2023 due to external economic factors, but the company remains optimistic and is focused on overcoming challenges through innovation and strategic adjustments [1][2]. Group 1: Performance and Financials - Mindray Medical hosted a research event with 382 institutions and 713 participants, discussing the company's performance and future strategies [1]. - Since its A-share listing in 2018, Mindray has achieved seven consecutive years of revenue and net profit growth, with 2024 revenue and net profit reaching 2.2 times and 2.5 times that of 2019, respectively [1]. - The company maintains a leading position in global market share for key products such as monitors, anesthesia machines, ventilators, defibrillators, blood products, and ultrasound devices [1]. Group 2: Research and Development - Mindray Medical invests approximately 10% of its revenue annually into R&D, with a record high investment of 4.008 billion yuan in 2024 [2]. - The R&D team consists of 5,000 members, positioning the company as a leader among domestic medical device firms and ensuring competitiveness in both domestic and international markets [2]. - The company focuses on high-end market demands, ranking third in the U.S. market for monitors and anesthesia machines, while also expanding into European and other overseas markets [2]. Group 3: Innovation and Technology - Mindray is actively integrating IT and AI technologies into its operations, creating differentiated advantages in smart healthcare [2]. - The application of vertical large models in ICU settings has improved diagnostic efficiency, with AI image reading accuracy exceeding 98% and efficiency being ten times that of manual processes [2]. - Historical experiences indicate that Mindray has successfully navigated challenges such as the 2008 financial crisis and the 2015 medical industry restructuring through policy adaptation and technological innovation [2].